Cisplatin and Cetuximab Treatment for Metastatic Cutaneous Squamous Cell Carcinoma

A Systematic Review

Cameron Trodello, Jon Paul Pepper, Michael Wong, Ashley Wysong

Research output: Contribution to journalReview article

14 Citations (Scopus)

Abstract

BACKGROUND Cutaneous squamous cell carcinoma (cSCC) is the second most common form of skin cancer and metastasizes in 2% to 5% of cases. OBJECTIVE Systematic evaluation of published cases of metastatic cSCC (mSCC) treated with cisplatin or cetuximab from 1989 to 2014. MATERIALS AND METHODS A literature search was performed to identify cases of mSCC treated with cisplatin or cetuximab. Patient demographics, tumor characteristics, response rates, and disease-free survivals were extracted. RESULTS A total of 60 cases of mSCC treated with cisplatin and 9 cases treated with cetuximab reported in the literature from 1989 to 2014 were included in the analysis. Patients treated with cetuximab obtained a complete response of 67%, an overall response of 78%, and a median disease-free survival of 25 (range 3-48) months. Patients treated with cisplatin obtained a complete response of 22%, an overall response of 45%, and a median disease-free survival of 14.6 (range 3-112) months. CONCLUSION Head-to-head prospective clinical studies between cetuximab and cisplatin are needed to determine which is more efficacious. In addition, prospective tumor registries and randomized controlled trials should be developed in order to establish the ideal systemic regimen in cSCC.

Original languageEnglish (US)
Pages (from-to)40-49
Number of pages10
JournalDermatologic Surgery
Volume43
Issue number1
DOIs
StatePublished - Jan 1 2017
Externally publishedYes

Fingerprint

Cisplatin
Squamous Cell Carcinoma
Skin
Disease-Free Survival
Therapeutics
Skin Neoplasms
Registries
Neoplasms
Randomized Controlled Trials
Demography
Cetuximab
Prospective Studies

ASJC Scopus subject areas

  • Surgery
  • Dermatology

Cite this

Cisplatin and Cetuximab Treatment for Metastatic Cutaneous Squamous Cell Carcinoma : A Systematic Review. / Trodello, Cameron; Pepper, Jon Paul; Wong, Michael; Wysong, Ashley.

In: Dermatologic Surgery, Vol. 43, No. 1, 01.01.2017, p. 40-49.

Research output: Contribution to journalReview article

Trodello, Cameron ; Pepper, Jon Paul ; Wong, Michael ; Wysong, Ashley. / Cisplatin and Cetuximab Treatment for Metastatic Cutaneous Squamous Cell Carcinoma : A Systematic Review. In: Dermatologic Surgery. 2017 ; Vol. 43, No. 1. pp. 40-49.
@article{1d1aaf354aee489ab3af70f0351a3167,
title = "Cisplatin and Cetuximab Treatment for Metastatic Cutaneous Squamous Cell Carcinoma: A Systematic Review",
abstract = "BACKGROUND Cutaneous squamous cell carcinoma (cSCC) is the second most common form of skin cancer and metastasizes in 2{\%} to 5{\%} of cases. OBJECTIVE Systematic evaluation of published cases of metastatic cSCC (mSCC) treated with cisplatin or cetuximab from 1989 to 2014. MATERIALS AND METHODS A literature search was performed to identify cases of mSCC treated with cisplatin or cetuximab. Patient demographics, tumor characteristics, response rates, and disease-free survivals were extracted. RESULTS A total of 60 cases of mSCC treated with cisplatin and 9 cases treated with cetuximab reported in the literature from 1989 to 2014 were included in the analysis. Patients treated with cetuximab obtained a complete response of 67{\%}, an overall response of 78{\%}, and a median disease-free survival of 25 (range 3-48) months. Patients treated with cisplatin obtained a complete response of 22{\%}, an overall response of 45{\%}, and a median disease-free survival of 14.6 (range 3-112) months. CONCLUSION Head-to-head prospective clinical studies between cetuximab and cisplatin are needed to determine which is more efficacious. In addition, prospective tumor registries and randomized controlled trials should be developed in order to establish the ideal systemic regimen in cSCC.",
author = "Cameron Trodello and Pepper, {Jon Paul} and Michael Wong and Ashley Wysong",
year = "2017",
month = "1",
day = "1",
doi = "10.1097/DSS.0000000000000799",
language = "English (US)",
volume = "43",
pages = "40--49",
journal = "Dermatologic Surgery",
issn = "1076-0512",
publisher = "Wiley-Blackwell",
number = "1",

}

TY - JOUR

T1 - Cisplatin and Cetuximab Treatment for Metastatic Cutaneous Squamous Cell Carcinoma

T2 - A Systematic Review

AU - Trodello, Cameron

AU - Pepper, Jon Paul

AU - Wong, Michael

AU - Wysong, Ashley

PY - 2017/1/1

Y1 - 2017/1/1

N2 - BACKGROUND Cutaneous squamous cell carcinoma (cSCC) is the second most common form of skin cancer and metastasizes in 2% to 5% of cases. OBJECTIVE Systematic evaluation of published cases of metastatic cSCC (mSCC) treated with cisplatin or cetuximab from 1989 to 2014. MATERIALS AND METHODS A literature search was performed to identify cases of mSCC treated with cisplatin or cetuximab. Patient demographics, tumor characteristics, response rates, and disease-free survivals were extracted. RESULTS A total of 60 cases of mSCC treated with cisplatin and 9 cases treated with cetuximab reported in the literature from 1989 to 2014 were included in the analysis. Patients treated with cetuximab obtained a complete response of 67%, an overall response of 78%, and a median disease-free survival of 25 (range 3-48) months. Patients treated with cisplatin obtained a complete response of 22%, an overall response of 45%, and a median disease-free survival of 14.6 (range 3-112) months. CONCLUSION Head-to-head prospective clinical studies between cetuximab and cisplatin are needed to determine which is more efficacious. In addition, prospective tumor registries and randomized controlled trials should be developed in order to establish the ideal systemic regimen in cSCC.

AB - BACKGROUND Cutaneous squamous cell carcinoma (cSCC) is the second most common form of skin cancer and metastasizes in 2% to 5% of cases. OBJECTIVE Systematic evaluation of published cases of metastatic cSCC (mSCC) treated with cisplatin or cetuximab from 1989 to 2014. MATERIALS AND METHODS A literature search was performed to identify cases of mSCC treated with cisplatin or cetuximab. Patient demographics, tumor characteristics, response rates, and disease-free survivals were extracted. RESULTS A total of 60 cases of mSCC treated with cisplatin and 9 cases treated with cetuximab reported in the literature from 1989 to 2014 were included in the analysis. Patients treated with cetuximab obtained a complete response of 67%, an overall response of 78%, and a median disease-free survival of 25 (range 3-48) months. Patients treated with cisplatin obtained a complete response of 22%, an overall response of 45%, and a median disease-free survival of 14.6 (range 3-112) months. CONCLUSION Head-to-head prospective clinical studies between cetuximab and cisplatin are needed to determine which is more efficacious. In addition, prospective tumor registries and randomized controlled trials should be developed in order to establish the ideal systemic regimen in cSCC.

UR - http://www.scopus.com/inward/record.url?scp=85009090900&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85009090900&partnerID=8YFLogxK

U2 - 10.1097/DSS.0000000000000799

DO - 10.1097/DSS.0000000000000799

M3 - Review article

VL - 43

SP - 40

EP - 49

JO - Dermatologic Surgery

JF - Dermatologic Surgery

SN - 1076-0512

IS - 1

ER -